Pfizer Inc. PFE, -0.09% gained 0.1% in premarket trading on Monday after the company said it is testing its experimental 20-valent pneumococcal conjugate vaccine in combination with a booster dose of its COVID-19 vaccine in adults who are 65 years old or older. The study includes 600 participants from the Phase 3 clinical trial for the COVID-19 vaccine. Both Pfizer and Moderna Inc. MRNA, +1.54% are testing booster doses for their two-dose, mRNA-based COVID-19 vaccines.
https://www.marketwatch.com/story/pfizer-is-testing-a-covid-19-booster-shot-in-combination-with-new-pneumococcal-conjugate-vaccine-candidate-2021-05-24
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.